| 1 |
NCT02049047 |
Active, not recruiting |
Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy |
- Thymoma and Thymic Carcinoma
|
|
Interventional |
Phase 2 |
- Armando Santoro, MD
- Istituto Clinico Humanitas
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- disease control rate
- PFS
- Duration of Response
- (and 4 more...)
|
41 |
All |
18 Years and older (Adult, Senior) |
NCT02049047 |
ONC-2010-001 |
ONC-2010-001 |
February 2011 |
April 2014 |
January 2019 |
January 29, 2014 |
November 6, 2017 |
|
- Istituto Clinico Humanitas
Rozzano, MI, Italy
|
| 2 |
NCT02623127 |
Active, not recruiting |
A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma |
|
|
Interventional |
Phase 2 |
- Seoul National University Hospital
- SMG-SNU Boramae Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Disease control rate
- Progression-Free Survival
- (and 2 more...)
|
25 |
All |
20 Years and older (Adult, Senior) |
NCT02623127 |
SNUBH-15-01 |
KOSMIC |
October 2015 |
October 2017 |
April 2018 |
December 7, 2015 |
April 27, 2017 |
|
- Seoul National University Bundang Hospital
Seongnam, Korea, Republic of
|
| 3 |
NCT02636556 |
Recruiting |
Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma |
- Thymoma and Thymic Carcinoma
|
- Radiation: concurrent chemoradiation
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival
- Objective response rate
- chemotherapy and radiation-induced toxicity assessed by CTCAE v4.0
|
56 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02636556 |
1508151-5 |
|
January 2013 |
June 2017 |
December 2017 |
December 21, 2015 |
March 1, 2017 |
|
- Kailiang Wu
Shanghai, Shanghai, China
|
| 4 |
NCT01011439 |
Active, not recruiting |
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma |
|
|
Interventional |
Phase 2 |
- Tiziana Life Sciences, PLC
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival rate at 3 months
- Overall safety profile
- Assessment of additional measures of tumor control to further characterize the efficacy profile of PHA-848125AC
- Explorative baseline characterization of biomarkers in tumor tissue of consenting patients
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT01011439 |
CDKO-125a-006
2009-014338-79 |
|
March 2009 |
October 2017 |
June 2019 |
November 11, 2009 |
July 18, 2017 |
|
- TGen Clinical Research Services at Scottsdale Healthcare
Scottsdale, Arizona, United States - NIH, Center for Cancer Research, Medical Oncology
Bethesda, Maryland, United States - Hopital Larrey
Toulouse Cedex, France - (and 3 more...)
|
| 5 |
NCT02633514 |
Recruiting |
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma |
- Thymoma and Thymic Carcinoma
|
- Drug: Cisplatin
- Drug: Etoposide
- Radiation: radiotherapy
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival
- Objective response rate
|
1 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02633514 |
1508151-6 |
|
November 2015 |
November 2018 |
|
December 17, 2015 |
August 12, 2016 |
|
- Kailiang Wu
Shanghai, Shanghai, China
|
| 6 |
NCT03134118 |
Not yet recruiting |
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) |
- Thymoma Type B3
- Thymic Carcinoma
|
|
Interventional |
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
- European Thoracic Oncology Platform
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival Rate (PFSR) at month 6
- Progression Free Survival (PFS)
- Overall Survival (OS)
- (and 4 more...)
|
55 |
All |
18 Years and older (Adult, Senior) |
NCT03134118 |
EORTC-1525
2015-005504-28
ETOP 11-16 |
NIVOTHYM |
April 2018 |
July 2021 |
July 2021 |
April 28, 2017 |
April 5, 2018 |
|
- Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland - UniversitaetsSpital Zurich
Zurich, Switzerland
|
| 7 |
NCT00965250 |
Completed
Has Results |
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy |
- Thymoma
- Thymic Carcinoma
- Thymic Carcinoid
- Thymic Neuroendocrine Tumors
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma.
- Number of Participants With Adverse Events
- Percentage of Participants Who Respond to Treatment
- (and 5 more...)
|
49 |
All |
18 Years and older (Adult, Senior) |
NCT00965250 |
090212
09-C-0212 |
|
August 2009 |
March 2012 |
June 2016 |
August 25, 2009 |
December 23, 2016 |
November 14, 2012 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 8 |
NCT01025089 |
Active, not recruiting |
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma |
- Thymoma
- Thymic Carcinoma
- Clinical Masaoka Stage II to IVA
|
- Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Eli Lilly and Company
- M.D. Anderson Cancer Center
- City of Hope National Medical Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the frequency of complete pathologic response to neo-adjuvant therapy with cisplatin, doxorubicin, cyclophosphamide (CAP) and cetuximab in patients with clinical Masaoka stage II-IVa thymoma and thymic carcinomas.
- To determine the toxicity (CTCAE v.3) of neo-adjuvant therapy with CAP and cetuximab
- To measure the radiographic response rate to cetuximab alone after 4 weeks
- (and 3 more...)
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT01025089 |
09-038 |
|
December 2009 |
December 2019 |
December 2019 |
December 3, 2009 |
April 6, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States - Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - (and 5 more...)
|
| 9 |
NCT00314873 |
Completed |
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma |
|
|
Interventional |
Phase 1 |
- Indiana University School of Medicine
- Indiana University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the objective response rate of imatinib in patients with c-kit or PDGF positive thymic carcinoma.
- To determine the duration of remission of patients with thymic carcinoma treated with imatinib.
- To determine the toxicity of imatinib in this patient population.
- To determine the incidence of kit mutations in thymic malignancies.
|
11 |
All |
18 Years and older (Adult, Senior) |
NCT00314873 |
0603-21/ IUCRO-0147 |
|
April 2006 |
March 2011 |
March 2011 |
April 17, 2006 |
June 3, 2014 |
|
- Indiana University Cancer Center
Indianapolis, Indiana, United States
|
| 10 |
NCT03076554 |
Recruiting |
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy |
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of Avelumab based on NCI-CTCAE v4.0
- Objective Response Rate (ORR) based on RECIST 1.1 criteria
- Immune-related progression-free survival (irPFS)
- (and 2 more...)
|
24 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03076554 |
170066
17-C-0066 |
|
April 19, 2017 |
September 30, 2019 |
September 30, 2020 |
March 10, 2017 |
March 19, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 11 |
NCT03295227 |
Recruiting |
Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma |
|
|
Interventional |
Phase 1 |
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity (DLT) of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
- Response Rate of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03295227 |
2017-0193 |
|
December 6, 2017 |
June 2019 |
June 2019 |
September 27, 2017 |
January 9, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 12 |
NCT02364076 |
Recruiting |
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma |
- Thymic Carcinoma
- Thymus Neoplasms
- Thymus Cancer
|
- Drug: Pembrolizumab
- Drug: Epacadostat
|
Interventional |
Phase 2 |
- Georgetown University
- Merck Sharp & Dohme Corp.
- Incyte Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Progression-free survival
- Overall survival
- Tolerability as measured by Adverse events and serious adverse events experienced by subjects
|
67 |
All |
18 Years and older (Adult, Senior) |
NCT02364076 |
2014-1315 |
|
March 2015 |
June 2021 |
December 2021 |
February 16, 2015 |
March 19, 2018 |
|
- Georgetown Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States
|
| 13 |
NCT00198133 |
Completed
Has Results |
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma |
|
- Drug: Premetrexed (Alimta)
|
Interventional |
Phase 2 |
- Patrick Joseph Loehrer Sr.
- Indiana University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (Complete and Partial Response)
- Duration of Remission
- Grade 3/4 Treatment Related Adverse Events
|
27 |
All |
18 Years and older (Adult, Senior) |
NCT00198133 |
0412-18; IUCRO-0088
IUCRO-0088 |
|
January 2005 |
December 2006 |
May 2012 |
September 20, 2005 |
January 25, 2016 |
January 25, 2016 |
- Indiana University Cancer Center
Indianapolis, Indiana, United States
|
| 14 |
NCT03449173 |
Recruiting |
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) |
- Type B3 Thymoma
- Thymic Carcinoma
|
|
Interventional |
Phase 2 |
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Activity of Sunitinib
- Progression Free Survival (PFS)
- Overall Survival (OS)
- (and 3 more...)
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT03449173 |
INT 165-16 |
Style |
March 2, 2017 |
March 2, 2021 |
March 2, 2021 |
February 28, 2018 |
March 27, 2018 |
|
- National Cancer Institute
Milan, Italy
|
| 15 |
NCT01301391 |
Active, not recruiting |
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy |
|
|
Interventional |
Phase 2 |
- Tiziana Life Sciences, PLC
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival rate at 3 months
- Adverse Events (NCI CTCAE) and hematological and blood chemistry parameters
- Objective Response Rate (ORR) by RECIST
- (and 3 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01301391 |
CDKO-125a-007 |
|
January 2011 |
October 2017 |
December 2018 |
February 23, 2011 |
July 18, 2017 |
|
- MedStar Georgetown University Hospital
Washington, D.C., District of Columbia, United States - NIH, Center for Cancer Research, Medical Oncology
Bethesda, Maryland, United States - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milano, (mi), Italy
|
| 16 |
NCT00818090 |
Terminated |
Paclitaxel and Cisplatin for Thymic Neoplasm |
|
- Drug: paclitaxel and cisplatin
|
Interventional |
Phase 2 |
- Korean Cancer Study Group
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- toxicity
- progression-free survival
- (and 2 more...)
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT00818090 |
KCSG-LU08-03; CRCST-L-0003 |
|
September 2008 |
November 2011 |
November 2011 |
January 7, 2009 |
April 12, 2013 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
| 17 |
NCT00010257 |
Completed
Has Results |
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma |
|
- Drug: carboplatin
- Drug: paclitaxel
|
Interventional |
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best Overall Response by RECIST Criteria (Version 1.0)
- Duration of Response
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT00010257 |
CDR0000068461
U10CA021115
E1C99 |
|
February 2001 |
November 2008 |
August 2012 |
January 27, 2003 |
October 9, 2015 |
October 18, 2012 |
- Rush-Copley Cancer Care Center
Aurora, Illinois, United States - Joliet Oncology-Hematology Associates, Limited - West
Joliet, Illinois, United States - Swedish-American Regional Cancer Center
Rockford, Illinois, United States - (and 64 more...)
|
| 18 |
NCT03463460 |
Not yet recruiting |
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer |
|
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Drug: Sunitinib Malate
|
Interventional |
Phase 2 |
- Dwight Owen
- National Cancer Institute (NCI)
- Ohio State University Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response defined by a complete response (CR) or partial response (PR) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Overall survival (OS)
- Progression free survival (PFS)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03463460 |
OSU-17234
NCI-2018-00192
P30CA016058 |
|
May 1, 2018 |
July 30, 2020 |
July 30, 2020 |
March 13, 2018 |
March 13, 2018 |
|
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
| 19 |
NCT00589290 |
Completed
Has Results |
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage |
|
- Drug: Belinostat (PDX101)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With a Partial Response
- Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer
- Number of Participants With Adverse Events
|
41 |
All |
18 Years and older (Adult, Senior) |
NCT00589290 |
080033
08-C-0033 |
|
December 2007 |
July 2013 |
June 2014 |
January 9, 2008 |
September 30, 2015 |
May 30, 2012 |
- Indiana University Cancer Center
Indianapolis, Indiana, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 20 |
NCT01621568 |
Active, not recruiting |
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment |
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- Indiana University School of Medicine
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the objective response rate (PR+CR) for sunitinib in patients with relapsed or refractory thymoma or thymic carcinoma
- To determine the progression-free survival and overall survival for sunitinib in patients with relapsed or refractory thymoma or thymic carcinoma.
- To assess safety and tolerability of sunitinib.
|
57 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01621568 |
120118
12-C-0118 |
|
April 18, 2012 |
April 30, 2018 |
April 30, 2019 |
June 18, 2012 |
April 5, 2018 |
|
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 21 |
NCT03466827 |
Recruiting |
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma |
- Thymoma
- Advanced Thymic Epithelial Tumour
|
|
Interventional |
Phase 2 |
- Morten Mau-Soerensen
- Institut Curie
- Gustave Roussy, Cancer Campus, Grand Paris
- (and 4 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Progression Free Survival
- Adverse Events
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT03466827 |
TET-SEL |
TET-SEL |
October 12, 2017 |
July 1, 2020 |
July 1, 2020 |
March 15, 2018 |
March 15, 2018 |
|
- Rigshospitalet
Copenhagen, Denmark - Hospices Civils de Lyon
Lyon, France - Intitut Curie
Paris, France - Intitut Gustave Roussy
Paris, France
|
| 22 |
NCT00387868 |
Completed |
Preoperative Treatment of Patients With High Risk Thymoma |
|
- Drug: cisplatin and etoposide
- Procedure: Surgical Resection
- Radiation: Concurrent Radiotherapy
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the complete pathologic response rate to peroperative cisplatin and etoposide given concurrently with radiation in patients with thymoma thought to be at high risk for recurrence
- Radiographic response to preoperative chemoradiotherapy by comparing pre and post treatment CT scans.
- Rate of complete resection following preoperative chemoradiotherapy as determined by pathologic examination of the specimen(s).
- (and 5 more...)
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT00387868 |
VHS07.0006a |
|
October 2006 |
October 2014 |
November 2014 |
October 13, 2006 |
December 9, 2014 |
|
- Valley Health System - The Valley Hospital
Ridgewood, New Jersey, United States - University of Toronto
Toronto, Ontario, Canada
|
| 23 |
NCT00003283 |
Completed |
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma |
- Thymoma and Thymic Carcinoma
|
- Drug: octreotide acetate
- Drug: prednisone
|
Interventional |
Phase 2 |
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT00003283 |
CDR0000066197
E-1C97 |
|
July 1998 |
September 2003 |
|
April 14, 2004 |
January 27, 2010 |
|
- Veterans Affairs Medical Center - Palo Alto
Palo Alto, California, United States - Stanford University Medical Center
Stanford, California, United States - CCOP - Colorado Cancer Research Program, Inc.
Denver, Colorado, United States - (and 22 more...)
|
| 24 |
NCT00369889 |
Completed |
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer |
|
- Drug: bevacizumab
- Drug: Erlotinib
|
Interventional |
Phase 2 |
- Indiana University School of Medicine
- Genentech, Inc.
- Indiana University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the objective response rate of the combination of erlotinib and bevacizumab in using RECIST.
- To determine the time to progression of patients previously treated with thymoma and thymic carcinoma treated with the combination of erlotinib and bevacizumab.
- To determine the toxicity of the combination of erlotinib and bevacizumab in this patient population.
- (and 4 more...)
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT00369889 |
IUCRO-0148 / 0606-20
AVF3891s
IUCRO-0148 |
|
August 2006 |
September 2007 |
September 2007 |
August 30, 2006 |
June 3, 2014 |
|
- Indiana University Cancer Center
Indianapolis, Indiana, United States
|
| 25 |
NCT00965627 |
Completed |
Biology of Thymic Tumors |
|
|
Observational |
|
- Istituto Clinico Humanitas
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Primary objective: to evaluate the presence of genetic alterations and specific potential therapy targets.
- Secondary objective: to correlate the biological characteristics with clinical characteristics and survival data of patients.
|
134 |
All |
18 Years and older (Adult, Senior) |
NCT00965627 |
ONC/OSS-01/2008 |
|
June 2008 |
August 2008 |
August 2009 |
August 25, 2009 |
August 28, 2009 |
|
- Istituto Clinico Humanitas
Rozzano, Milano, Italy
|
| 26 |
NCT00718809 |
Terminated
Has Results |
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer |
- Invasive Thymoma and Thymic Carcinoma
- Recurrent Thymoma and Thymic Carcinoma
- Stage III Thymoma
- (and 2 more...)
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (Complete and Partial Response)
- Progression-free Survival
- Overall Survival
- (and 2 more...)
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT00718809 |
NCI-2009-00297
IUCRO-0214 |
|
June 2008 |
August 2010 |
October 2013 |
July 21, 2008 |
June 10, 2015 |
June 10, 2015 |
- Stanford University Hospitals and Clinics
Stanford, California, United States - Indiana University Medical Center
Indianapolis, Indiana, United States
|
| 27 |
NCT01364727 |
Active, not recruiting
Has Results |
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies |
- Thymoma
- Thymus Cancer
- Thymic Carcinoma
|
|
Interventional |
Phase 2 |
- Heather Wakelee
- Celgene
- Stanford University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Overall Response Rate (ORR)
- Median Progression-free Survival (PFS)
- Disease Control Rate (DCR)
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT01364727 |
IRB-20444
SU-01142011-7369
THOR0003 |
|
June 2011 |
July 2014 |
December 2017 |
June 2, 2011 |
April 17, 2017 |
March 14, 2017 |
- Stanford University School of Medicine
Stanford, California, United States - Indiana University
Indianapolis, Indiana, United States
|
| 28 |
NCT03078699 |
Completed |
Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment |
|
- Radiation: stereotactic body radiation therapy
|
Interventional |
Not Applicable |
- Third Military Medical University
|
Other |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS (progression-free time)
- Tumor response rate
|
32 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03078699 |
PSSBRT |
|
January 1, 2005 |
January 1, 2014 |
September 1, 2016 |
March 13, 2017 |
March 13, 2017 |
|
- Daping Hospital, Third Military Medical University
Chongqing, Chongqing, China
|
| 29 |
NCT01143545 |
Completed |
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas |
- Lung Cancer
- Esophageal Cancer
- Malignant Pleural Mesothelioma
- (and 2 more...)
|
- Biological: Allogeneic Tumor Cell Vaccine (K562)
- Drug: Celecoxib
- Drug: cyclophosphamide
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tabulation of toxicity type and grade
- To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.
- To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.
|
10 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01143545 |
100138
10-C-0138 |
|
May 31, 2010 |
February 9, 2015 |
March 19, 2015 |
June 14, 2010 |
April 17, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 30 |
NCT01100944 |
Terminated
Has Results |
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies |
|
- Drug: PXD101with cisplatin+doxorubicin+cyclophosphamide
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Belinostat
- Number of Participants With Grade 3 and 4 Dose Limiting Toxicity (DLT) at 2000mg/m(2) Belinostat
- Objective Response Rate (Partial Response (PR) + Complete Response (CR) of Belinostat in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Patients With Advanced Thymic Malignancies
- (and 18 more...)
|
26 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01100944 |
100077
10-C-0077 |
|
March 4, 2010 |
October 21, 2015 |
October 21, 2015 |
April 9, 2010 |
August 10, 2017 |
November 15, 2016 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 31 |
NCT01312324 |
Completed |
Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer |
- Locally Advanced Stage III or IV Thymic Cancer
|
- Drug: neoadjuvant docetaxel/cisplatin
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete resection rate
- the number of patients with adverse events
|
27 |
All |
18 Years and older (Adult, Senior) |
NCT01312324 |
2007-01-040 |
|
February 2007 |
July 2015 |
March 2016 |
March 10, 2011 |
April 20, 2016 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 32 |
NCT03212027 |
Not yet recruiting |
Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Different DWI parameters in thymic epithelial tumors
- To acquire aquaporins expression level of thymic epithelial tumors
|
60 |
All |
Child, Adult, Senior |
NCT03212027 |
2016SF-211 |
|
July 31, 2017 |
January 1, 2018 |
May 1, 2018 |
July 11, 2017 |
July 18, 2017 |
|
|
| 33 |
NCT00003662 |
Completed |
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases |
- Graft Versus Host Disease
- Leukemia
- Myelodysplastic Syndromes
- Thymic Carcinoma
|
- Biological: anti-thymocyte globulin
- Drug: busulfan
- Drug: cyclophosphamide
- (and 5 more...)
|
Interventional |
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
90 |
All |
Child, Adult, Senior |
NCT00003662 |
CDR0000066755
P30CA016056
RPCI-RP-9803
NCI-G98-1486 |
|
August 1998 |
January 2001 |
January 2001 |
August 4, 2004 |
March 7, 2011 |
|
- University of Florida Health Science Center
Gainesville, Florida, United States - Division of Pediatric Surgery
Jacksonville, Florida, United States - H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States - (and 12 more...)
|
| 34 |
NCT02214134 |
Recruiting |
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access |
- Any Stage of Lung Cancer (Any Histotype)
- Any Stage of Malignant Pleural Mesothelioma
- Any Stage of Any Thymic Malignancy
|
- Genetic: Tumour markers testing
|
Observational |
|
- European Organisation for Research and Treatment of Cancer - EORTC
- European Thoracic Oncology Platform
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.
- Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.
- Number of exploratory/future research projects developped
|
3500 |
All |
18 Years and older (Adult, Senior) |
NCT02214134 |
EORTC-1335-LCG-PBG |
SPECTAlung |
May 2015 |
January 2019 |
January 2019 |
August 12, 2014 |
January 19, 2017 |
|
- Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, Belgium - Universitair Ziekenhuis Antwerpen
Edegem, Belgium - U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium - (and 14 more...)
|
| 35 |
NCT03193437 |
Recruiting |
Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy |
- Thymoma
- Advanced Thymic Epithelial Tumor
|
- Drug: Open Label Selinexor
|
Interventional |
Phase 2 |
- Georgetown University
- Hackensack University Medical Center
- Karyopharm Therapeutics Inc
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Progression Free Survival
- Overall Survival
- Adverse Events
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT03193437 |
2016-0622 |
SELECT |
April 3, 2018 |
December 2019 |
December 2020 |
June 20, 2017 |
April 9, 2018 |
|
- Georgetown Lombardi Comprehensive Cancer Center
Washington, District of Columbia, United States
|
| 36 |
NCT00024076 |
Completed |
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer |
- Lung Cancer
- Malignant Mesothelioma
- Metastatic Cancer
- Thymoma and Thymic Carcinoma
|
- Procedure: radiofrequency ablation
|
Interventional |
Phase 2 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
30 |
All |
Child, Adult, Senior |
NCT00024076 |
CDR0000068889
P30CA016042
UCLA-9908024
NCI-G01-2011 |
|
May 2000 |
December 2006 |
|
January 27, 2003 |
October 30, 2015 |
|
- Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States
|
| 37 |
NCT02810418 |
Recruiting |
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors |
- Neoplasms
- Pancreatic Neoplasms
|
- Drug: LMB-100
- Drug: Nab-Paclitaxel
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate in phase 2 subjects of short infusion LMB-100+ nab-paclitaxel
- Maximum tolerated dose of short infusion LMB-100 + nab paclitaxel
- Maximum tolerated dose of continuous infusion LMB-100
- (and 7 more...)
|
100 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02810418 |
160128
16-C-0128 |
|
June 22, 2016 |
April 30, 2021 |
January 31, 2022 |
June 23, 2016 |
March 2, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 38 |
NCT01283945 |
Completed |
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors |
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Objective response rate (CR and PR according to RECIST) and rate of non-progressive disease at 24 weeks
- Pharmacokinetics following single and multiple dose administration
- (and 5 more...)
|
134 |
All |
18 Years and older (Adult, Senior) |
NCT01283945 |
E-3810-I-01 |
|
July 2010 |
September 2016 |
May 4, 2017 |
January 26, 2011 |
April 12, 2018 |
|
- Institute Gustave Roussy
Villejuif, Paris, France - Hopital Louis Pradel
Lyon, France - European Institute of Oncology
Milano, Italy - Vall d' Hebron University Hospital
Barcellona, Spain
|
| 39 |
NCT01950572 |
Recruiting |
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma |
- Mesothelioma
- Thymoma
- Pancreatic Neoplasms
- (and 2 more...)
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
1000 |
All |
2 Years to 100 Years (Child, Adult, Senior) |
NCT01950572 |
130202
13-C-0202 |
|
September 21, 2013 |
December 31, 2030 |
December 31, 2030 |
September 25, 2013 |
March 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 40 |
NCT03170804 |
Recruiting |
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer |
- Thyroid Nodule
- Thyroid Cancer
- Thyroid Diseases
- Thymic Carcinoma
|
|
Observational |
|
- Aventura Hospital and Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- prognostic value of Thyroseq v2 molecular/genomic profiling
|
200 |
All |
16 Years and older (Child, Adult, Senior) |
NCT03170804 |
20162786 |
|
January 1, 2017 |
January 1, 2018 |
January 1, 2020 |
May 31, 2017 |
May 31, 2017 |
|
- Aventura Hospital and Medical Center
Aventura, Florida, United States
|
| 41 |
NCT03102320 |
Recruiting |
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors |
|
- Drug: Cisplatin
- Drug: Gemcitabine
- Drug: Anetumab ravtansine (BAY94-9343)
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine in patients with mesothelin-expressing cholangiocarcinoma and pancreatic adenocarcinoma
- Objective response rate (ORR) of anetumab ravtansine for monotherapy and combination therapy in mesothelin expressing advanced solid tumors
- Number of serious and non-serious adverse events (AEs)
- (and 4 more...)
|
348 |
All |
18 Years and older (Adult, Senior) |
NCT03102320 |
15834
2016-004002-33 |
ARCS-Multi |
May 26, 2017 |
May 31, 2019 |
February 11, 2020 |
April 5, 2017 |
February 19, 2018 |
|
- Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - Mayo Clinic Hospital
Phoenix, Arizona, United States - University of Southern California
Los Angeles, California, United States - (and 95 more...)
|
| 42 |
NCT00003336 |
Completed |
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions |
- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases
|
- Biological: anti-thymocyte globulin
- Drug: busulfan
- Drug: cyclophosphamide
- (and 5 more...)
|
Interventional |
Phase 2 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival by disease assessment
- Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC) at time of myeloid recovery.
|
6 |
All |
up to 55 Years (Child, Adult) |
NCT00003336 |
CWRU5Y97
P30CA043703
CASE-CWRU-5Y97
NCI-G98-1431
CASE-5Y97 |
|
January 1998 |
December 2005 |
February 2006 |
January 27, 2003 |
June 11, 2010 |
|
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 43 |
NCT02054104 |
Suspended |
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum |
- Lung Cancer
- Esophageal Cancer
- Malignant Pleural Mesothelioma
- (and 2 more...)
|
- Biological: H1299 Lysate Vaccine
- Drug: Cyclophosphamide
- Drug: Celecoxib
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of immune response rates in patients taking vaccine alone versus those taking vaccine plus metronomic chemotherapy.
- Determine whether oral metronomic cyclophosphamide andcelecoxib therapy diminishes the percentage and number of Tregulatory cells and diminishes activity of these cells in patientswith thoracic malignancies
- Determine whether H1299 cell lysate/Iscomatrix vaccinationenhances immunologic response to autologous tumor orepigenetically modified autologous EBV-transformed lymphocytes(B cells)
|
21 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02054104 |
140053
14-C-0053 |
|
February 1, 2014 |
November 5, 2020 |
November 5, 2020 |
February 4, 2014 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 44 |
NCT00921739 |
Active, not recruiting |
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies |
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Thymoma
- Thymus Neoplasms
|
- Radiation: Esophageal sparing IMRT
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of IMRT
- The occurrence of RT-induced acute esophagitis
- To determine if biological predictors of esophagitis can identify patients who develop severe esophageal toxicity during radiation therapy
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00921739 |
Pro00017361 |
ESIMRT |
August 2009 |
December 2014 |
December 2018 |
June 16, 2009 |
March 16, 2018 |
|
- Duke University Medical Center
Durham, North Carolina, United States
|
| 45 |
NCT01385722 |
Enrolling by invitation |
Molecular Analysis of Thoracic Malignancies |
- Thymus Cancer
- Thymoma
- Thymic Carcinoma
- (and 3 more...)
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Collect detailed clinical information on patients with thoracic malignancies via the electronic medical record and a detailed patient questionnaire
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT01385722 |
THOR0004
SU-06232011-7986
21319 |
|
August 2011 |
June 2031 |
June 2031 |
June 30, 2011 |
March 22, 2018 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
| 46 |
NCT02062632 |
Active, not recruiting |
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy |
- Esophageal Carcinoma
- Hypopharyngeal Carcinoma
- Laryngeal Carcinoma
- (and 11 more...)
|
- Drug: Doxepin Hydrochloride
- Other: Placebo
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
|
Interventional |
Not Applicable |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Change in mouth pain using a 0 to 10 numerical analogue scale
- Incidence of any grade 3 or higher adverse events using Common Terminology Criteria for Adverse Events (CTCAE)
- Incidence of any grade 3 or higher adverse event rates using Radiation Therapy Oncology Group
- (and 4 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02062632 |
MC13C1
NCI-2014-00253
P30CA015083 |
|
April 14, 2014 |
October 14, 2018 |
October 14, 2018 |
February 14, 2014 |
December 4, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States - University of Nebraska Medical Center
Omaha, Nebraska, United States - Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, United States
|
| 47 |
NCT00372840 |
Unknown † |
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer |
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- (and 4 more...)
|
- Other: educational intervention
- Procedure: psychosocial assessment and care
- Procedure: quality-of-life assessment
|
Interventional |
Not Applicable |
- Fox Chase Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Uptake of recommended actions
- Number of sections of the Facing Forward manual read with satisfaction and comprehension
- Changes in psychological outcomes from baseline to 8-week follow-up
|
332 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00372840 |
FCCC-FCRB-04-002-P
CDR0000464245
NCI-2009-00569
06-803 |
|
May 2006 |
November 2010 |
|
September 7, 2006 |
March 3, 2016 |
|
- Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States
|
| 48 |
NCT00154388 |
Completed |
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases |
- Life Threatening Diseases
|
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases
- To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease
- To assess the safety and tolerability of Imatinib mesylate
- (and 2 more...)
|
185 |
All |
15 Years to 70 Years (Child, Adult, Senior) |
NCT00154388 |
CSTI571B2225 |
|
February 2001 |
January 2007 |
January 2007 |
September 12, 2005 |
November 18, 2016 |
|
|
| 49 |
NCT00538850 |
Completed
Has Results |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
|
- Drug: Fentanyl sublingual spray
- Drug: Placebo
|
Interventional |
Phase 3 |
- INSYS Therapeutics Inc
- National Cancer Institute (NCI)
|
Industry / NIH |
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)
- Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing
- Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing
- Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT00538850 |
INS-05-001
CDR0000581128 |
|
October 2007 |
February 2010 |
October 2010 |
October 3, 2007 |
March 5, 2014 |
March 5, 2014 |
- InSys Therapeutics, Incorporated
Chandler, Arizona, United States
|
| 50 |
NCT00066404 |
Unknown † |
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions |
|
- Biological: recombinant adenovirus-hIFN-beta
|
Interventional |
Phase 1 |
- Abramson Cancer Center of the University of Pennsylvania
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00066404 |
CDR0000315899
UPCC-01502 |
|
April 2003 |
|
|
August 7, 2003 |
August 10, 2010 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
Create an RSS feed from your search for:
Download the search results for: